Syntara Limited (SNT.AX)

0.0180 +0.0030 (+20.00%) At close: 04:10PM AEST

Syntara Limited

20 Rodborough Road
Frenchs Forest, NSW 2086
Australia
61 2 9454 7200
https://www.syntaratx.com.au

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 27

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Gary Jonathan Phillips BPharm, MBA	CEO, MD & Director	618.81k	N/A	1961
Mr. David Morris McGarvey BA, CA, CPA	CFO & Company Secretary	482.44k	N/A	1956
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D.	Head of Drug Discovery	470.89k	N/A	1964
Ms. Kristen Morgan B.Sc., BSc, MMedSc, PGDipBusAdmin	Head of Medical & Regulatory Affairs - Alliance Management	277.66k	N/A	1972
Dr. Jana Baskar	Chief Medical Officer	406.2k	N/A	N/A
Mr. Cameron David Billingsley BA, LLB (Hons.)	General Counsel	N/A	N/A	1977

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Corporate Governance

Syntara Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.